Form 4 for PFE Pfizer
Accepted 2023-02-24 00:00:00 ET · period of report 2023-02-22 · accession 0001225208-23-002832 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-02-24 | 2023-02-22 | PFE | Hwang Angela | Pres, Gbl Biopharmaceu | F - Tax | $43.45 | -42.8K | 24.3K | -64% | -$1.86M |
| D | 2023-02-24 | 2023-02-22 | PFE | Hwang Angela | Pres, Gbl Biopharmaceu | M - OptEx | $30.17 | +57.0K | 67.0K | +571% | +$1.72M |
| DM | 2023-02-24 | 2023-02-23 | PFE | Hwang Angela | Pres, Gbl Biopharmaceu | A - Grant | $0.00 | +193.2K | 89.9K | New | $0 |
| D | 2023-02-24 | 2023-02-22 | PFE | Hwang Angela | Pres, Gbl Biopharmaceu | M - OptEx | $0.00 | -57.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-22 | F | D | 8,041 | $42.38 | 58,986 | D | — | — | (F2) The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. |
| 2 | Common | Common Stock | 2023-02-22 | F | D | 34,718 | $43.70 | 24,268 | D | — | — | (F3) The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). (F4) Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. |
| 3 | Common | Common Stock | 2023-02-22 | M | A | 57,032 | $30.17 | 67,027 | D | — | — | (F1) The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). |
| 4 | Derivative | Stock Appreciation Rights | 2023-02-23 | A | A | 103,320 | $0.00 | 103,320 | D | $42.30 · 2028-02-23 to 2028-02-23 | 103,320 Common Stock | (F6) The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. |
| 5 | Derivative | Stock Appreciation Rights | 2023-02-22 | M | D | 57,032 | $0.00 | 0 | D | $30.17 · 2023-02-22 to 2023-02-22 | 57,032 Common Stock | |
| 6 | Derivative | Stock Appreciation Rights | 2023-02-23 | A | A | 89,920 | $0.00 | 89,920 | D | $42.30 · 2030-02-23 to 2030-02-23 | 89,920 Common Stock | (F7) The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. |